We are Catalonia BioHT!
The video presentation of Oxolife as a new member of CataloniaBio Health Tech has already come to light. We are very grateful to CataloniaBio for producing the video and for helping us to make our project known worldwide!It is a pleasure to work with you.
OXOLIFE will participate in the ESHRE 37th Annual Meeting
At the end of June, the European Society of Human Reproduction and Embryology (ESHRE) organizes its 37th Annual Meeting and OXOLIFE will participate in it. It is fantastic news that the ESHRE has accepted our communication “Oral administration of OXO-001 to a swine model improves embryo implantation rate”, which contains information about OXO-001 in vivo preclinical studies. […]
OXOLIFE AND IBEC START AN STRATEGIC ALLIANCE TO STUDY OXO-001 IMPLANTATION ACTIVITY
Fresh news! Today it has been published in La Vanguardia the collaboration between OXOLIFE and the Open Innovation Laboratory – Institute for Bioengineering of Catalonia (IBEC) led by Dr. Samuel Ojosnegros. Our aim is to improve embryo implantation with OXO-001 and to expand knowledge of this process. #growwithus MORE INFORMATION
BIOTECH COMPANY OXOLIFE AND UNIVERSITY OF CORDOBA ARE TESTING A NEW DRUG TO IMPROVE FERTILITY IN WOMEN WITH POLYCYSTIC OVARY
Oxolife has established a collaboration with the Energy Balance, Puberty and Reproductive Health Group of the University of Cordoba (UCO), with the aim of evaluating the potential of the drug OXO-001. At the same time, to carry out this line of research, a collaboration has been established with the Maimonides Institute for Biomedical Research (Imibic), […]
OXOLIFE RECEIVES SEAL OF EXCELLENCE FROM THE EUROPEAN COMMISSION
OXOLIFE is celebrating. The European Commission has awarded us with the “Seal of Excellence” for our project “FIRST-IN CLASS DRUG TO ENHANCE FEMALE EMBRYO IMPLANTATION” submitted under the Horizon 2020’s SME Instrument. A great encouragement for all the team that a panel of independent international experts value our project as innovative, trustful and with a clear outline for […]
OXOLIFE, 1 OF THE 10 NEW STARTUPS WITH HIGHEST POTENCIAL
Experts from fields related to emerging companies in the technological, biomedical and industrial environment, have chosen the ten 2020 emerging companies located in Catalonia. The clinical-stage startup Oxolife focused on fertility has been included in the list. MORE INFORMATION
BIOTECHNOLOGY THAT HELPS WOMEN TO BECOME MOTHER
Oxolife, an emerging biotechnology company, is the first to focus on promoting the implantation of embryo in the endometrium, an unmet medical need. MORE INFORMATION
HAS BEEN SELECTED BY THE EUROPEAN EIT HEALTH HEADSTART 2020 FUNDING PROGRAM
96 start-ups will receive mentoring and financial support to accelerate the development of promising health solutions. Oxolife’s project to enhance embryo implantation is one of the 16 Spanish companies awarded. MORE INFORMATION
FINANCIAL TIMES: “OXOLIFE IS ONE OF THE 20 SPANISH HEALTHCARE COMPANIES TO WATCH”
The Barcelona based, women’s fertility startup has developed a molecule, OXO-001, that enhances embryo implantation improving female fertility rates. MORE INFORMATION
lINTERVIEW IN CATALUNYA RADIO. REVOLUCIÓ 4.0
Interview with Agnès Arbat, Oxolife’s CEO and co-founder, presenting the selected startup of the BStartup Health program from Banc Sabadell. MORE INFORMATION